Literature DB >> 26475546

Pyoderma gangrenosum and inflammatory bowel disease: A cross-sectional inpatient socioeconomic study.

David W Brodell1, John C Elfar2, Mary Gail Mercurio3.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26475546      PMCID： PMC5839169          DOI： 10.1016/j.jaad.2015.08.009

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  4 in total

1.  Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study.

Authors:  Sinéad M Langan; Richard W Groves; Tim R Card; Martin C Gulliford
Journal:  J Invest Dermatol       Date:  2012-04-26       Impact factor: 8.551

2.  Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.

Authors:  T N Brooklyn; M G S Dunnill; A Shetty; J J Bowden; J D L Williams; C E M Griffiths; A Forbes; R Greenwood; C S Probert
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

Review 3.  Etiology and management of pyoderma gangrenosum: a comprehensive review.

Authors:  Iris Ahronowitz; Joanna Harp; Kanade Shinkai
Journal:  Am J Clin Dermatol       Date:  2012-06-01       Impact factor: 7.403

Review 4.  Pyoderma gangrenosum: an updated review.

Authors:  E Ruocco; S Sangiuliano; A G Gravina; A Miranda; G Nicoletti
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-03-11       Impact factor: 6.166
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.